• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

原发性中枢神经系统淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

作者信息

Ferreri Andreas J M, Illerhaus Gerald, Doorduijn Jeanette K, Auer Dorothee P, Bromberg Jacoline E C, Calimeri Teresa, Cwynarski Kate, Fox Christopher P, Hoang-Xuan Khê, Malaise Denis, Ponzoni Maurilio, Schorb Elisabeth, Soussain Carole, Specht Lena, Zucca Emanuele, Buske Christian, Jerkeman Mats, Dreyling Martin

机构信息

Lymphoma Unit, IRCCS San Raffaele Scientific Institute Milan Italy.

Università Vita e Salute San Raffaele Milan Italy.

出版信息

Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89. eCollection 2024 Jun.

DOI:10.1002/hem3.89
PMID:38836097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11148853/
Abstract

This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS.The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.Algorithms for first-line and salvage treatments are provided.The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe.Recommendations are based on available scientific data and the authors' collective expert opinion.

摘要

本欧洲血液学协会-欧洲肿瘤内科学会临床实践指南为中枢神经系统原发性弥漫性大B细胞淋巴瘤的管理提供了关键建议。该指南涵盖临床、影像学和病理诊断、分期及风险评估、治疗与随访。提供了一线治疗和挽救治疗的算法。作者团队包括来自欧洲不同机构和国家的多学科专家小组。建议基于现有科学数据和作者的集体专家意见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/4dd34dda9341/HEM3-8-e89-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/95395a06393b/HEM3-8-e89-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/9da75b936927/HEM3-8-e89-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/460affc001e4/HEM3-8-e89-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/4dd34dda9341/HEM3-8-e89-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/95395a06393b/HEM3-8-e89-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/9da75b936927/HEM3-8-e89-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/460affc001e4/HEM3-8-e89-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf3/11148853/4dd34dda9341/HEM3-8-e89-g004.jpg

相似文献

1
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发性中枢神经系统淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89. eCollection 2024 Jun.
2
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.人类免疫缺陷病毒相关淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Hemasphere. 2024 Sep 3;8(9):e150. doi: 10.1002/hem3.150. eCollection 2024 Sep.
3
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发性中枢神经系统淋巴瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2024 May 14. doi: 10.1016/j.annonc.2023.11.010.
4
Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up".《原发性中枢神经系统淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南》勘误
Hemasphere. 2024 Jul 22;8(7):e118. doi: 10.1002/hem3.118. eCollection 2024 Jul.
5
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.人类免疫缺陷病毒相关淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2024 Oct;35(10):840-859. doi: 10.1016/j.annonc.2024.06.003. Epub 2024 Sep 3.
6
Clinical Practice Guideline: Sudden Hearing Loss (Update).临床实践指南：突发性聋（更新）。
Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45. doi: 10.1177/0194599819859885.
7
Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.临床实践指南：突发性聋（更新）执行摘要。
Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.国际循证指南关于多囊卵巢综合征评估和管理的推荐意见。
Fertil Steril. 2018 Aug;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004. Epub 2018 Jul 19.
10
Evidence-based guideline: unexplained infertility†.基于证据的指南：不明原因不孕†。
Hum Reprod. 2023 Oct 3;38(10):1881-1890. doi: 10.1093/humrep/dead150.

引用本文的文献

1
Primary Central Nervous System B-Cell Lymphoma Presenting with Fluctuating Basal Ganglia and Cortical Lesions.表现为基底节和皮质病变波动的原发性中枢神经系统B细胞淋巴瘤
J Belg Soc Radiol. 2025 Aug 18;109(1):33. doi: 10.5334/jbsr.4044. eCollection 2025.
2
Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy.采用联合免疫化疗及全脑放疗治疗原发性中枢神经系统淋巴瘤的疗效
Ann Hematol. 2025 Aug 25. doi: 10.1007/s00277-025-06561-1.
3
[Staging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin lymphomas].

本文引用的文献

1
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.随机 III 期研究：高剂量甲氨蝶呤和全脑放疗联合/不联合替莫唑胺治疗新诊断的原发性中枢神经系统淋巴瘤：JCOG1114C。
Neuro Oncol. 2023 Apr 6;25(4):687-698. doi: 10.1093/neuonc/noac246.
2
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.原发中枢神经系统淋巴瘤患者年龄 60 岁及以下采用放疗或自体造血干细胞移植治疗：前瞻性随机 II 期 PRECIS 研究的长期结果。
J Clin Oncol. 2022 Nov 10;40(32):3692-3698. doi: 10.1200/JCO.22.00491. Epub 2022 Jul 14.
3
[非霍奇金淋巴瘤的放射学和核医学分期及治疗反应评估]
Radiologie (Heidelb). 2025 May 28. doi: 10.1007/s00117-025-01459-5.
4
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.189例复发/难治性原发性中枢神经系统淋巴瘤患者使用替拉布替尼的上市后监测。
Future Oncol. 2025 Jun;21(15):1837-1847. doi: 10.1080/14796694.2025.2507561. Epub 2025 May 27.
5
In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.在靶向治疗和免疫治疗时代：免疫豁免部位大B细胞淋巴瘤的治疗进展
Front Immunol. 2025 Apr 1;16:1547377. doi: 10.3389/fimmu.2025.1547377. eCollection 2025.
6
Consolidation therapy impact on survival outcomes in young patients with intracranial primary diffuse large B-cell lymphoma achieving complete remission: a propensity score matching analysis.巩固治疗对颅内原发性弥漫性大B细胞淋巴瘤达到完全缓解的年轻患者生存结局的影响：一项倾向评分匹配分析
Front Oncol. 2025 Mar 31;15:1493542. doi: 10.3389/fonc.2025.1493542. eCollection 2025.
7
Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid.通过微创检测脑脊液中的ctDNA指导中枢神经系统淋巴瘤患者的临床管理。
Leukemia. 2025 May;39(5):1265-1268. doi: 10.1038/s41375-025-02583-w. Epub 2025 Apr 9.
8
Intraoperative classification of CNS lymphoma and glioblastoma by AI-based analysis of Stimulated Raman Histology (SRH).通过基于人工智能的受激拉曼组织学（SRH）分析对中枢神经系统淋巴瘤和胶质母细胞瘤进行术中分类。
Brain Spine. 2025 Jan 26;5:104187. doi: 10.1016/j.bas.2025.104187. eCollection 2025.
9
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.使用利妥昔单抗和大剂量甲氨蝶呤进行预阶段治疗，以重新评估中枢神经系统淋巴瘤体弱患者强化诱导治疗的 eligibility。（注：这里“eligibility”结合语境推测可能是“适用性”之类的意思，但按要求未做意译，直接保留原文词汇）
Haematologica. 2025 Jun 1;110(6):1384-1388. doi: 10.3324/haematol.2024.286347. Epub 2025 Jan 23.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
5
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.MATRix 方案后继自体移植治疗原发性中枢神经系统淋巴瘤的长期疗效、安全性和神经耐受性：IELSG32 随机试验 7 年结果。
Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.
6
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.tisagenlecleucel 在原发性中枢神经系统淋巴瘤中的安全性和疗效：一项 1/2 期临床试验。
Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738.
7
CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.嵌合抗原受体T细胞疗法治疗原发性中枢神经系统淋巴瘤：法国LOC网络的临床经验
Blood. 2022 Feb 3;139(5):792-796. doi: 10.1182/blood.2021012932.
8
Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.利妥昔单抗-来那度胺-依鲁替尼联合治疗复发/难治性原发性中枢神经系统淋巴瘤：LOC 网络的病例系列。
Neurology. 2021 Sep 28;97(13):628-631. doi: 10.1212/WNL.0000000000012515.
9
Primary vitreoretinal lymphoma: a diagnostic and management challenge.原发性玻璃体视网膜淋巴瘤：诊断和治疗的挑战。
Blood. 2021 Oct 28;138(17):1519-1534. doi: 10.1182/blood.2020008235.
10
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.原发性中枢神经系统淋巴瘤患者自体造血细胞移植后应用噻替哌预处理的结果。
JAMA Oncol. 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074.